nRichDX to Exhibit Innovations at AACR Annual Meeting 2025
The cutting-edge leader in liquid biopsy sample preparation, nRichDX, is excited to announce its participation in the American Association for Cancer Research (AACR) Annual Meeting 2025. This prestigious event will take place at the McCormick Place Convention Center, gathering cancer research professionals from around the globe.
Introducing the Revolution Plus Instrument
This year, nRichDX will showcase its latest advancements, including the Revolution Plus Instrument, which epitomizes their commitment to enhancing the usability and effectiveness of liquid biopsy assays. Attendees can find nRichDX at booth #4641, where they will showcase a host of innovative kits and compelling data.
Focus on Liquid Biopsy Solutions
nRichDX has been recognized for its expertise in liquid biopsy applications. The firm will present groundbreaking solutions that allow for enhanced extraction of cell-free DNA (cfDNA), circulating cell-free RNA (cfRNA), and circulating tumor cells (CTCs). These advancements are particularly significant for researchers interested in improving the efficiency and accuracy of cancer diagnostic procedures.
Insights from Company Leadership
William Curtis, CEO of nRichDX, expressed enthusiasm about the upcoming meeting, stating, "nRichDX is setting the standard for liquid biopsy sample preparation performance, workflow, and flexibility with solutions engineered to easily deliver the highest yields of rare analytes from an unequaled range of sample types and volumes." This statement highlights the company's dedication to innovation in the cancer research field.
New Features of the nRicher Cartridges
Among the company’s latest offerings are two new nRicher Cartridges designed for single extractions that accommodate a wide volume range from 1 mL to 100 mL. This innovation eliminates the need for sample pooling and transfer steps, ensuring maximum yield from each sample.
Demonstrations and Collaboration Opportunities
nRichDX will co-present a research poster in collaboration with PacBio, emphasizing the comprehensive capabilities of their systems. Attendees are encouraged to stop by booth #4641 to engage with nRichDX team members and explore offering demonstrations that illustrate the power of the Revolution Plus System.
To better understand these innovations, interested parties can also schedule an appointment with nRichDX staff during the event for an in-depth discussion regarding their latest products.
About nRichDX
nRichDX provides exceptional solutions for isolating cfDNA, cfRNA, and CTCs, significantly enhancing the reliability of liquid biopsies. Their Revolution Sample Prep System is specifically crafted for handling various biofluids, ensuring high yield and recovery rates.
For further details regarding nRichDX's participation and to stay updated, interested individuals can access the company's platform online.
Frequently Asked Questions
What is the AACR Annual Meeting?
The AACR Annual Meeting is a significant event that gathers cancer researchers from various sectors to discuss the latest advancements and breakthroughs in cancer research.
What will nRichDX be presenting at the conference?
nRichDX will present their new products, including the Revolution Plus Instrument and nRicher Cartridges, showcasing enhanced liquid biopsy solutions.
Where can attendees find nRichDX at the AACR event?
Attendees can find nRichDX at booth #4641 during the AACR Annual Meeting 2025.
How can researchers benefit from nRichDX's offerings?
Researchers can learn about techniques that enhance the extraction of analytes from samples, leading to improved performance of diagnostic assays.
Who is the CEO of nRichDX?
William Curtis serves as the CEO of nRichDX and is actively engaged in promoting the company's innovative solutions within the field of liquid biopsy research.
